Stericycle (NASDAQ:SRCL) Price Target Cut to $55.00

Stericycle (NASDAQ:SRCL) had its price objective trimmed by Robert W. Baird from $62.00 to $55.00 in a report published on Friday morning, Benzinga reports. The firm currently has a neutral rating on the business services provider’s stock.

A number of other equities research analysts have also issued reports on the company. Wells Fargo & Company upped their target price on Stericycle from $40.00 to $48.00 and gave the company an underweight rating in a research note on Friday, March 1st. Stifel Nicolaus upped their target price on Stericycle from $70.00 to $75.00 and gave the company a buy rating in a research note on Thursday, February 29th. Truist Financial increased their price target on Stericycle from $50.00 to $57.00 and gave the stock a hold rating in a research note on Thursday, February 29th. Royal Bank of Canada reissued an outperform rating and set a $69.00 price target on shares of Stericycle in a research note on Thursday, March 7th. Finally, StockNews.com lowered Stericycle from a buy rating to a hold rating in a research note on Tuesday, April 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of Hold and a consensus price target of $60.80.

Stericycle Trading Down 0.4 %

SRCL opened at $46.31 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.94 and a current ratio of 1.11. The stock’s 50 day simple moving average is $51.35 and its 200 day simple moving average is $48.17. Stericycle has a 1-year low of $37.78 and a 1-year high of $57.06.

Stericycle (NASDAQ:SRCL) last posted its earnings results on Thursday, April 25th. The business services provider reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.03. Stericycle had a positive return on equity of 7.31% and a negative net margin of 0.74%. The firm had revenue of $664.90 million for the quarter, compared to analyst estimates of $676.42 million. During the same quarter in the prior year, the company earned $0.49 EPS. Stericycle’s revenue was down 2.8% on a year-over-year basis. On average, sell-side analysts anticipate that Stericycle will post 2.32 earnings per share for the current year.

Institutional Trading of Stericycle

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Citigroup Inc. increased its holdings in shares of Stericycle by 0.6% during the 3rd quarter. Citigroup Inc. now owns 46,953 shares of the business services provider’s stock worth $2,099,000 after buying an additional 285 shares during the last quarter. Strategic Blueprint LLC increased its holdings in shares of Stericycle by 6.5% during the 3rd quarter. Strategic Blueprint LLC now owns 5,283 shares of the business services provider’s stock worth $236,000 after buying an additional 322 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Stericycle by 4.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 7,243 shares of the business services provider’s stock worth $359,000 after buying an additional 336 shares during the last quarter. Retirement Systems of Alabama increased its holdings in shares of Stericycle by 0.3% during the 4th quarter. Retirement Systems of Alabama now owns 115,880 shares of the business services provider’s stock worth $5,743,000 after buying an additional 355 shares during the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of Stericycle by 1.4% during the 3rd quarter. Arizona State Retirement System now owns 26,322 shares of the business services provider’s stock worth $1,177,000 after buying an additional 358 shares during the last quarter. 98.82% of the stock is currently owned by institutional investors and hedge funds.

About Stericycle

Stericycle, Inc, together with its subsidiaries, provides regulated waste and compliance services in the United States, Europe, and internationally. The company offers regulated waste and compliance services, including regulated medical waste, sharps waste management and disposal, pharmaceutical waste management and disposal, chemotherapy waste and disposal, controlled substance waste disposal, healthcare hazardous waste, and integrated waste stream solutions; specialty services, such as MedDrop medication collection kiosks, safe community solutions, SafeDrop sharps mailback solutions, and airport and maritime waste services; medical supply store services, that includes sharps and disposable biohazardous waste containers, infection control supplies, and seal&send medication mail back; and compliance solutions including Steri-Safe compliance solutions.